Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (38)
Norah Layla Sadek, Bruno Almeida Costa, Karthik Nath & Sham Mailankody. (2023) CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review. Clinical Pharmacology & Therapeutics.
Crossref
Crossref
Yang Xing, Feroza Yasinjan, Yajie Du, Huayue Geng, Ying Zhang, Minghua He, Rui Guo, Lei Yang, Jiayue Cui, Dongmei Mu, Ziling Liu & Hong Wang. (2023) Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials. Frontiers in Immunology 14.
Crossref
Crossref
Sadegh Shojaei Baghini, Zhanna R. Gardanova, Saeme Azizi Hassan Abadi, Burhan Abdullah Zaman, Ahmet İlhan, Navid Shomali, Ali Adili, Roozbeh Moghaddar & Amirhossein Fakhre Yaseri. (2022) CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool. Cellular & Molecular Biology Letters 27:1.
Crossref
Crossref
Marzieh Nikoo, Mohammad Rudiansyah, Dmitry Olegovich Bokov, Nurlan T. Jainakbaev, Wanich Suksatan, Mohammad Javed Ansari, Lakshmi Thangavelu, Supat Chupradit, Amir Zamani, Ali Adili, Navid Shomali & Morteza Akbari. (2022)
Potential of chimeric antigen receptor (
CAR
)‐redirected immune cells in breast cancer therapies: Recent advances
. Journal of Cellular and Molecular Medicine 26:15, pages 4137-4156.
Crossref
Crossref
Asal Barshidi, Vahid Karpisheh, Fatemeh Karimian Noukabadi, Fariba Karoon Kiani, Mohammad Mohammadi, Negin Afsharimanesh, Farbod Ebrahimi, Seyed Hossein Kiaie, Jamshid Gholizadeh Navashenaq, Mohammad Hojjat-Farsangi, Naime Majidi Zolbanin, Ata Mahmoodpoor, Hadi Hassannia, Sanam Nami, Pooya Jalali, Reza Jafari & Farhad Jadidi-Niaragh. (2022) Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model. Pharmaceutical Research 39:8, pages 1851-1866.
Crossref
Crossref
Xiaofeng Dai, Jitian Li, Yiming Chen & Kostya (Ken) Ostrikov. (2022) When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies. Frontiers in Oncology 12.
Crossref
Crossref
Luyao Wang, Yurong Chen, Xinrui Liu, Ziyi Li & Xiangpeng Dai. (2022) The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems. Frontiers in Oncology 11.
Crossref
Crossref
Sara Adibfar, Marischa Elveny, Hadisha Sh. Kashikova, Maria Vladimirovna Mikhailova, Pooya Farhangnia, Sajjad Vakili-Samiani, Hanieh Tarokhian & Farhad Jadidi-Niaragh. (2021) The molecular mechanisms and therapeutic potential of EZH2 in breast cancer. Life Sciences 286, pages 120047.
Crossref
Crossref
Vahid Karpisheh, Seyedeh Mahboubeh Mousavi, Parinaz Naghavi Sheykholeslami, Mehrdad Fathi, Mehran Mohammadpour Saray, Leili Aghebati-Maleki, Reza Jafari, Naime Majidi Zolbanin & Farhad Jadidi-Niaragh. (2021) The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. Life Sciences 284, pages 119132.
Crossref
Crossref
Louise Ferrall, Ken Y. Lin, Richard B.S. Roden, Chien-Fu Hung & T.-C. Wu. (2021) Cervical Cancer Immunotherapy: Facts and Hopes. Clinical Cancer Research 27:18, pages 4953-4973.
Crossref
Crossref
Nina Miazek-Zapala, Aleksander Slusarczyk, Aleksandra Kusowska, Piotr Zapala, Matylda Kubacz, Magdalena Winiarska & Malgorzata Bobrowicz. (2021) The “Magic Bullet” Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells 10:6, pages 1511.
Crossref
Crossref
Xingxing Yuan, Zujun Sun, Qingyun Yuan, Weihua Hou, Qiaoyan Liang, Yuxiong Wang, Wei Mo, Huijie Wang & Min Yu. (2020) Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors. Investigational New Drugs 39:1, pages 34-51.
Crossref
Crossref
Young Dong Yu & Tae Jin Kim. (2021) Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review. International Journal of Molecular Sciences 22:2, pages 640.
Crossref
Crossref
Chang Wu & Jun Wu. (2021) Chimeric Antigen Receptor (CAR) T Cell Therapy for Digestive Tumor. E3S Web of Conferences 271, pages 03065.
Crossref
Crossref
Mitra Ghasemi‐Chaleshtari, Seyed Hossein Kiaie, Mahzad Irandoust, Hadis Karami, Mohsen Nabi Afjadi, Sepideh Ghani, Nasimeh Aghaei Vanda, Mohammad Javad Ghaderi Sede, Armin Ahmadi, Ali Masjedi, Hadi Hassannia, Fatemeh Atyabi, Mohammad Hojjat‐Farsangi, Afshin Namdar, Ghasem Ghalamfarsa & Farhad Jadidi‐Niaragh. (2020) Concomitant blockade of A2AR and CTLA‐4 by siRNA‐loaded polyethylene glycol‐chitosan‐alginate nanoparticles synergistically enhances antitumor T‐cell responses. Journal of Cellular Physiology 235:12, pages 10068-10080.
Crossref
Crossref
Negar Hosseinkhani, Afshin Derakhshani, Omid Kooshkaki, Mahdi Abdoli Shadbad, Khalil Hajiasgharzadeh, Amir Baghbanzadeh, Hossein Safarpour, Ahad Mokhtarzadeh, Oronzo Brunetti, Simon Yue, Nicola Silvestris & Behzad Baradaran. (2020) Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. International Journal of Molecular Sciences 21:21, pages 8305.
Crossref
Crossref
Danhua Luo. (2020) Chimeric Antigen Receptor T-Cell Immunotherapy for Cancer. Chimeric Antigen Receptor T-Cell Immunotherapy for Cancer.
Sepideh Izadi, Afshin Nikkhoo, Mohammad Hojjat-Farsangi, Afshin Namdar, Gholamreza Azizi, Hamed Mohammadi, Mehdi Yousefi & Farhad Jadidi-Niaragh. (2020) CDK1 in Breast Cancer: Implications for Theranostic Potential. Anti-Cancer Agents in Medicinal Chemistry 20:7, pages 758-767.
Crossref
Crossref
Vida Hashemi, Shohreh Farhadi, Mitra Ghasemi Chaleshtari, Brinton Seashore-Ludlow, Ali Masjedi, Mohammad Hojjat-Farsangi, Afshin Namdar, Amir Ajjoolabady, Hamed Mohammadi, Ghasem Ghalamfarsa & Farhad Jadidi-Niaragh. (2020) Nanomedicine for improvement of dendritic cell-based cancer immunotherapy. International Immunopharmacology 83, pages 106446.
Crossref
Crossref
Vida Hashemi, Armin Ahmadi, Farinaz Malakotikhah, Mitra Ghasemi Chaleshtari, Mahdi Baghi Moornani, Ali Masjedi, Mozhdeh Sojoodi, Fatemeh Atyabi, Afshin Nikkhoo, Narges Rostami, Behzad Baradaran, Gholamreza Azizi, Bahman Yousefi, Ghasem Ghalamfarsa & Farhad Jadidi-Niaragh. (2020) Silencing of p68 and STAT3 synergistically diminishes cancer progression. Life Sciences 249, pages 117499.
Crossref
Crossref
Shima Bastaki, Mahzad Irandoust, Armin Ahmadi, Mohammad Hojjat-Farsangi, Patrick Ambrose, Shahin Hallaj, Mahdi Edalati, Ghasem Ghalamfarsa, Gholamreza Azizi, Mehdi Yousefi, Hengameh Chalajour & Farhad Jadidi-Niaragh. (2020) PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. Life Sciences 247, pages 117437.
Crossref
Crossref
Hao Ling. (2020) Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumor. IOP Conference Series: Materials Science and Engineering 768:5, pages 052051.
Crossref
Crossref
Carolina Simioni, Fabio Bergamini, Martina Ferioli, Erika Rimondi, Lorenzo Caruso & Luca M. Neri. (2019) New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances. Hematological Oncology 38:1, pages 22-33.
Crossref
Crossref
Vida Hashemi, Leili Aghebati Maleki, Maryam Esmaily, Ali Masjedi, Ghasem Ghalamfarsa, Afshin Namdar, Mehdi Yousefi, Bahman Yousefi & Farhad Jadidi-Niaragh. (2020) Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. International Immunopharmacology 78, pages 106087.
Crossref
Crossref
Natalie S. Grover & Barbara Savoldo. (2019) Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer 19:1.
Crossref
Crossref
Seyed Mohammad Hosseini, Isobel Okoye, Mitra Ghasemi Chaleshtari, Bita Hazhirkarzar, Javad Mohamadnejad, Gholamreza Azizi, Mohammad Hojjat-Farsangi, Hamed Mohammadi, Siamak Sandoghchian Shotorbani & Farhad Jadidi-Niaragh. (2019) E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions. Clinica Chimica Acta 498, pages 126-134.
Crossref
Crossref
Fatemeh Hajari Taheri, Mahmoud Hassani, Zahra Sharifzadeh, Mehdi Behdani, Arash Arashkia & Mohsen Abolhassani. (2019) T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy. IUBMB Life 71:9, pages 1259-1267.
Crossref
Crossref
Luyao Wang, Ruixue Yao, Lifa Zhang, Chuanbo Fan, Leina Ma & Jia Liu. (2019) Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity. International Immunopharmacology 70, pages 498-503.
Crossref
Crossref
Jun Liu, Xi Zhang, Jiang F Zhong & Cheng Zhang. (2019) Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation. Immunotherapy 11:1, pages 37-44.
Crossref
Crossref
Jonathan Ozik, Nicholson Collier, Justin M. Wozniak, Charles Macal, Chase Cockrell, Samuel H. Friedman, Ahmadreza Ghaffarizadeh, Randy Heiland, Gary An & Paul Macklin. (2018) High-throughput cancer hypothesis testing with an integrated PhysiCell-EMEWS workflow. BMC Bioinformatics 19:S18.
Crossref
Crossref
Susan T Sharfstein. (2018) Non-protein biologic therapeutics. Current Opinion in Biotechnology 53, pages 65-75.
Crossref
Crossref
Jinjing Xu, Yali Wang, Jing Shi, Juan Liu, Qingguo Li & Longzhou Chen. (2018) Combination therapy: A feasibility strategy for CAR‑T cell therapy in the treatment of solid tumors (Review). Oncology Letters.
Crossref
Crossref
Jinjing Xu, Qing Zhang, Kang Tian, Haiyu Wang, Hong Yin & Junnian Zheng. (2017) Current status and future prospects of the strategy of combining CAR‑T with PD‑1 blockade for antitumor therapy (Review). Molecular Medicine Reports.
Crossref
Crossref
Alissar El Chediak, Ali Shamseddine, Larry Bodgi, Jean-Pierre Obeid, Fady Geara & Youssef H. Zeidan. (2017) Optimizing tumor immune response through combination of radiation and immunotherapy. Medical Oncology 34:9.
Crossref
Crossref
Yongxian Hu, Zhao Wu, Yi Luo, Jimin Shi, Jian Yu, Chengfei Pu, Zuyu Liang, Guoqing Wei, Qu Cui, Jie Sun, Jing Jiang, Jue Xie, Yamin Tan, Wanmao Ni, Jifang Tu, Jinping Wang, Aiyun Jin, Hao Zhang, Zhen Cai, Lei Xiao & He Huang. (2017) Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia. Clinical Cancer Research 23:13, pages 3297-3306.
Crossref
Crossref
Andrew Yang, Emily Farmer, John Lin, T.-C. Wu & Chien-Fu Hung. (2017) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Research 231, pages 148-165.
Crossref
Crossref
F. Eckert, U.S. Gaipl, G. Niedermann, M. Hettich, K. Schilbach, S.M. Huber & D. Zips. (2017) Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation. Clinical and Translational Radiation Oncology 2, pages 29-35.
Crossref
Crossref
Farhad Jadidi-Niaragh, Fatemeh Atyabi, Ali Rastegari, Esmail Mollarazi, Melika Kiani, Alireza Razavi, Mehdi Yousefi, Nasim Kheshtchin, Hadi Hassannia, Jamshid Hadjati & Fazel Shokri. (2016) Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles. Tumor Biology 37:6, pages 8403-8412.
Crossref
Crossref